Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Dermatology | Endocrinology | Family Medicine | Internal Medicine | Nursing | Journal

Back to Journal Articles

Psoriasis Independently Linked to Risk of Type 2 Diabetes

Last Updated: June 19, 2012.

 

Dose-dependent link; patients with severe psoriasis more likely to receive diabetes pharmacotherapy

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Psoriasis is an independent risk factor for the development of type 2 diabetes mellitus, and this risk increases with increasing severity of psoriasis, according to a study published online June 18 in the Archives of Dermatology.

TUESDAY, June 19 (HealthDay News) -- Psoriasis is an independent risk factor for the development of type 2 diabetes mellitus, and this risk increases with increasing severity of psoriasis, according to a study published online June 18 in the Archives of Dermatology.

To assess the risk of incident diabetes mellitus in patients with psoriasis, Rahat S. Azfar, M.D., from the University of Pennsylvania in Philadelphia, and colleagues analyzed electronic medical records for 108,132 patients with psoriasis (aged 18 to 90 years) and 430,716 matched, unexposed controls. Only patients who developed incident diabetes mellitus during the study time frame were included.

The researchers found that the fully adjusted hazard ratios for incident diabetes mellitus were 1.14 overall, 1.11 in the mild psoriasis group, and 1.46 in the severe psoriasis group. The adjusted risk for receiving diabetes mellitus pharmacotherapy was 1.55 among those with incident diabetes and severe psoriasis.

"Further research into the extent to which psoriasis and its treatment play a role in the development of type 2 diabetes mellitus and its complications is warranted," the authors write. "In addition, it is necessary to determine why patients with severe psoriasis who develop diabetes mellitus are more likely to receive prescription hypoglycemic treatments."

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text

Copyright © 2012 HealthDay. All rights reserved.


Previous: High Future Coronary Event Risk in Chronic Kidney Disease Next: AACR: New Treatments Studied for Pancreatic Cancer

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.